{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:40:10Z","timestamp":1749940810194,"version":"3.41.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Cannabidiol (CBD) is one of the major centrally active phytocannabinoid components of cannabis, and has been approved by the FDA only for the treatment of seizures associated with three rare disorders. It has also been touted as a potential treatment for anxiety in place of more traditional treatments like benzodiazepines. Although there is some evidence of anxiolytic effects of CBD, its suitability as a substitute for benzodiazepines is unknown. This experiment was designed to assess the extent to which CBD shares interoceptive discriminative-stimulus properties with the anxiolytic drug chlordiazepoxide (CDP), a benzodiazepine. In the present experiment, a range of doses (0-1569\u2005mg\/kg) of over-the-counter CBD oil was administered (i.g.) in male Sprague\u2013Dawley rats trained to discriminate 5.6\u2005mg\/kg CDP from saline. Due to the long time-course effects of CBD, generalization tests were conducted at 90 and 120\u2009min post-CBD administration. The two highest doses of CBD tested (1064 and 1569\u2005mg\/kg) were found to partially substitute for 5.6\u2005mg\/kg CDP, with mean percent responding on the CDP-associated lever reaching above 20% at time 2 (120\u2009min post-CBD administration), suggesting that high doses of the over-the-counter CBD oils used in this experiment share interoceptive discriminative-stimulus properties to some degree with CDP. These results are novel in comparison to existing research into stimulus effects of CBD, in which substitution for benzodiazepines has not previously been observed.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000762","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T18:10:00Z","timestamp":1702404600000},"page":"36-46","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Discriminative-stimulus effects of cannabidiol oil in Sprague-Dawley rats"],"prefix":"10.1097","volume":"35","author":[{"given":"Rebecca L.","family":"Chalm\u00e9","sequence":"first","affiliation":[{"name":"Division on Substance Use Disorders, New York State Psychiatric Institute and Department of Psychiatry, Vagelos College of Physicians and Surgeons of Columbia University, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Frankot","sequence":"additional","affiliation":[{"name":"Department of Psychology, West Virginia University, Morgantown, West Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen G.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Psychology, West Virginia University, Morgantown, West Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"e00682","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD.","volume":"8","author":"de Almeida","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(99)00597-X","article-title":"Cocaine discrimination and time-course effects in male and female Wistar rats.","volume":"382","author":"Anderson","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0163-7258(90)90090-O","article-title":"Drug discrimination models in anxiety and depression.","volume":"47","author":"Andrews","year":"1990","journal-title":"Pharmacol Ther"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors.","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol Res"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4.","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online.","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","article-title":"Cannabidiol: pharmacology and therapeutic targets.","volume":"238","author":"Britch","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pbb.2008.12.017","article-title":"Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats.","volume":"92","author":"Bruner","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.bjp.0706796","article-title":"Mechanism of action of benzodiazepines on GABAA receptors.","volume":"148","author":"Campo-Soria","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/can.2018.0030","article-title":"Regulatory status of cannabidiol in the United States: a perspective.","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/can.2018.0006","article-title":"A cross-sectional study of cannabidiol users.","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/j.pain.0000000000001386","article-title":"Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.","volume":"160","author":"De Gregorio","year":"2019","journal-title":"Pain"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/jeab.507","article-title":"Applying mixed-effects modeling to single-subject designs: an introduction.","volume":"111","author":"DeHart","year":"2019","journal-title":"J Exp Anal Behav"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","article-title":"Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), \u03949-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavior.","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1901\/jeab.1962.5-529","article-title":"A progression for generating variable-interval schedules.","volume":"5","author":"Fleshler","year":"1962","journal-title":"J Exp Anal Behav"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41386-023-01592-6","article-title":"Statistical power and false positive rates for interdependent outcomes are strongly influenced by test type","volume":"48","author":"Frankot","year":"2023","journal-title":"Neuropsychopharmacol"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2131\/jts.43.451","article-title":"Generalization tests using different dosing routes from those of drug discrimination training in rats.","volume":"43","author":"Fujiwara","year":"2018","journal-title":"J Toxicol Sci"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/biom10111575","article-title":"Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders.","volume":"10","author":"Garc\u00eda-Guti\u00e9rrez","year":"2020","journal-title":"Biomolecules"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"158110","DOI":"10.1016\/j.scitotenv.2022.158110","article-title":"Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products.","volume":"851","author":"Gardener","year":"2022","journal-title":"Sci Total Environ"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.yebeh.2019.07.008","article-title":"Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.","volume":"98","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav"},{"key":"R27-20250614","first-page":"392","article-title":"Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment.","volume":"35","author":"Goldenberg","year":"2010","journal-title":"P T"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.121.000988","article-title":"Preclinical assessment of the abuse potential of purified botanical cannabidiol: self-administration, drug discrimination, and physical dependence.","volume":"382","author":"Gray","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02244012","article-title":"Antianxiety effect of cannabidiol in the elevated plus-maze.","volume":"100","author":"Guimar\u00e3es","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0091-3057(99)00054-4","article-title":"GTS-21, a mixed nicotinic receptor agonist\/antagonist, does not affect the nicotine cue.","volume":"64","author":"van Haaren","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.euroneuro.2017.10.037","article-title":"Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.","volume":"27","author":"Hlo\u017eek","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"108615","DOI":"10.1016\/j.yebeh.2022.108615","article-title":"Partial protective effects of cannabidiol against PTZ-induced acute seizures in female rats during the proestrus\u2013estrus transition.","volume":"129","author":"Janisset","year":"2022","journal-title":"Epilepsy Behav"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42238-022-00140-1","article-title":"Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs label claim.","volume":"4","author":"Johnson","year":"2022","journal-title":"J Cannabis Res"},{"key":"R57-20250614","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.","volume":"41","author":"Linares","year":"2019","journal-title":"Braz J Psychiatry"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0149-7634(94)90039-6","article-title":"Antidepressant-like behavioral effects of serotonin receptor agonists.","volume":"18","author":"Lucki","year":"1994","journal-title":"Neurosci Biobehav Rev"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3758\/s13428-016-0809-y","article-title":"Evaluating significance in linear mixed-effects models in R.","volume":"49","author":"Luke","year":"2017","journal-title":"Behav Res Methods"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s002130050646","article-title":"Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents.","volume":"138","author":"Marona-Lewicka","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.drugalcdep.2015.04.001","article-title":"The rise (and fall?) of drug discrimination research.","volume":"151","author":"McMahon","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: an overview of some pharmacological aspects.","volume":"42","author":"Mechoulam","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"108514","DOI":"10.1016\/j.yebeh.2021.108514","article-title":"Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: implications for patients and practitioners.","volume":"127","author":"Miller","year":"2022","journal-title":"Epilepsy Behav"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42238-021-00061-5","article-title":"Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems.","volume":"3","author":"Moltke","year":"2021","journal-title":"J Cannabis Res"},{"key":"R43-20250614","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","article-title":"Pharmacodynamic drug\u2013drug interactions.","volume":"105","author":"Niu","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R44-20250614","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1055\/s-2007-1014370","article-title":"Preclinical evidence on the psychotropic profile of fluvoxamine.","volume":"26","author":"Olivier","year":"1993","journal-title":"Pharmacopsychiatry"},{"key":"R45-20250614","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-3-540-74806-9_16","article-title":"Midazolam and other benzodiazepines.","volume":"182","author":"Olkkola","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"R46-20250614","first-page":"1002","article-title":"Pharmacological characterization of cannabinoids in the elevated plus-maze.","volume":"253","author":"Onaivi","year":"1990","journal-title":"Pharmacology"},{"key":"R58-20250614","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/epi.17000","article-title":"Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial.","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"R47-20250614","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbr.2006.05.016","article-title":"Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats.","volume":"172","author":"Resstel","year":"2006","journal-title":"Behav Brain Res"},{"key":"R48-20250614","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/epi.14574","article-title":"A novel GABAergic dysfunction in human Dravet syndrome.","volume":"59","author":"Ruffolo","year":"2018","journal-title":"Epilepsia"},{"key":"R49-20250614","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","article-title":"The benzodiazepine binding sites of GABAA receptors.","volume":"39","author":"Sigel","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"R51-20250614","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"R52-20250614","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/ijms23010094","article-title":"Anticonvulsive effects and pharmacokinetic profile of cannabidiol (CBD) in the pentylenetetrazol (PTZ) or N-methyl-D-aspartate (NMDA) models of seizures in infantile rats.","volume":"23","author":"Uttl","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R53-20250614","doi-asserted-by":"crossref","first-page":"108827","DOI":"10.1016\/j.drugalcdep.2021.108827","article-title":"\u03949-Tetrahydrocannabinol discrimination: effects of route of administration in rats.","volume":"225","author":"Wiley","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"R54-20250614","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/BF00439549","article-title":"Discriminative stimulus properties of midazolam: comparison with other benzodiazepines.","volume":"97","author":"Woudenberg","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"R56-20250614","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jeab.316","article-title":"Discounting: a practical guide to multilevel analysis of choice data.","volume":"109","author":"Young","year":"2018","journal-title":"J Exp Anal Behav"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:01:26Z","timestamp":1749938486000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000762","relation":{},"ISSN":["0955-8810"],"issn-type":[{"type":"print","value":"0955-8810"}],"subject":[],"published":{"date-parts":[[2023,12,13]]}}}